Guardant Health, Inc. (GH)
NASDAQ: GH · Real-Time Price · USD
44.05
-2.80 (-5.98%)
May 5, 2025, 4:00 PM EDT - Market closed
Guardant Health Stock Forecast
Stock Price Forecast
The 21 analysts with 12-month price forecasts for Guardant Health stock have an average target of 52.33, with a low estimate of 32 and a high estimate of 70. The average target predicts an increase of 18.80% from the current stock price of 44.05.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Guardant Health stock from 21 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 10 | 11 | 11 | 11 | 11 |
| Buy | 6 | 5 | 8 | 9 | 10 | 10 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17 | 15 | 19 | 20 | 21 | 21 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Scotiabank | Scotiabank | Buy Maintains $52 → $57 | Buy | Maintains | $52 → $57 | +29.40% | May 5, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $60 → $65 | Strong Buy | Maintains | $60 → $65 | +47.56% | May 1, 2025 |
| Stifel | Stifel | Strong Buy Maintains $53 → $60 | Strong Buy | Maintains | $53 → $60 | +36.21% | May 1, 2025 |
| Barclays | Barclays | Buy Maintains $55 → $60 | Buy | Maintains | $55 → $60 | +36.21% | May 1, 2025 |
| TD Securities | TD Securities | Strong Buy Maintains $56 → $60 | Strong Buy | Maintains | $56 → $60 | +36.21% | May 1, 2025 |
Financial Forecast
Revenue This Year
883.38M
from 739.02M
Increased by 19.53%
Revenue Next Year
1.08B
from 883.38M
Increased by 21.92%
EPS This Year
-3.14
from -3.56
EPS Next Year
-2.54
from -3.14
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 913.5M | 1.2B | 1.5B | ||
| Avg | 883.4M | 1.1B | 1.3B | ||
| Low | 825.6M | 980.0M | 1.1B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 23.6% | 30.9% | 42.0% | ||
| Avg | 19.5% | 21.9% | 23.3% | ||
| Low | 11.7% | 10.9% | -1.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.15 | -1.13 | -0.37 | ||
| Avg | -3.14 | -2.54 | -1.90 | ||
| Low | -3.47 | -3.10 | -2.54 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.